Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 20, 2026

Prometheus Energetics Breaks Ground on New Solid Rocket Motor Manufacturing Campus in Indiana

View original at finance.yahoo.com
Prometheus Energetics Breaks Ground on New Solid Rocket Motor Manufacturing Campus in Indiana BLOOMFIELD, Ind. , Feb. 20, 2026 /PRNewswire/ -- Prometheus Energetics, LLC, a U.S.-based merchant supplier of solid rocket motors (SRMs) and energetics and a joint venture between Kratos Defense & Security Solutions, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Prometheus is projected to begin SRM production in 2027

    80% confidence

  • Breaking ground on this campus reflects shared commitment with RAFAEL to invest own dollars to rapidly stand up trusted, domestic production capacity that can operate at scale

    80% confidence

  • The Prometheus campus represents Rafael's approach to localized and resilient production in response to modern defense requirements

    80% confidence

  • This campus is foundational to ensuring readiness is more than a promise, it is a certainty

    80% confidence

  • The United States faces a growing gap in solid rocket motor and energetics production, representing a national security vulnerability

    80% confidence

  • At Kratos, affordability is a technology, utilizing proven leading edge approaches and technology to reduce cost, schedule and risk

    80% confidence

  • Today's groundbreaking represents the moment when a known vulnerability in America's solid rocket motor supply chain begins to be closed

    80% confidence

  • Prometheus was created to operate at production scale, delivering trusted, domestically produced energetics systems to meet urgent and long-term U.S. and allied defense needs

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com